Table 1 Implementation and feasibility measures
Variable | Measure (for both POC and HIV DNA PCR tests, unless specified) | EID stage(s) |
|---|---|---|
Acceptability/uptake | Mothers’ views of birth testing impact on infant, family | |
Provider recommendations/concerns on implementation | ||
Community member attitudes and recommendations | ||
Proportion (%) infants with specimen collected | Birth, 6 weeksa | |
Median infant age at specimen collection | Birth, 6 weeks | |
% Birth-tested infants returned for 6-week retest | Sequential | |
Infant testing outcomes | % Tests with results returned | Birth, 6 weeks |
% Tests with mother notified of results | Birth, 6 weeks | |
Median turn-around time (TAT), specimen to test result availability | Birth, 6 weeks | |
Median infant age at result availability | Birth, 6 weeks | |
Median TAT, result availability to mother notification of results | Birth, 6 weeks | |
Median overall TAT, specimen to mother notification of results | Birth, 6 weeks | |
Median infant age at mother notification of results | Birth, 6 weeks | |
Median infant age at ART initiation (if diagnosed HIV+) | Birth, 6 weeks | |
Complete retention: % mothers notified of birth and 6-week results | Sequential | |
POC platform performance | Number failed POC tests, GeneXpert and Alere q | Pooled |
Number POC missed opportunities due to machine breakdown | Pooled | |
Number POC missed opportunities due to machine error | Pooled | |
Number POC missed opportunities due to cartridge stockout | Pooled | |
Concordance of POC results (each platform) with HIV DNA PCR | Birth, 6 weeks | |
Provider feedback | Acceptability and feasibility of implementing birth and POC testing | |
Benefits and challenges of birth and POC testing for patients | ||
Costs of POC implementation | Acquisition of GeneXpert and Alere q machines | |
Acquisition of accessory equipment | ||
Site-specific training, secure storage | ||
Acquisition of test cartridges | ||
Maintenance and repair of machines |